Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins
José María Soberanes Diez, Carolina S. Romero, Maria Cristina Cruz, et al.
The Journal of Infectious Diseases (2021) Vol. 225, Iss. 6, pp. 938-946
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases
Sareh Kakavandi, Iman Zare, Maryam Vaezjalali, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 61
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques
Rajeshwer S. Sankhala, Kerri G. Lal, Jaime L. Jensen, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 31
OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model
Charlotte Primard, Élodie Monchâtre-Leroy, Judith del Campo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
SARS‐CoV‐2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design
Faezeh Maghsood, Ahmad Ghorbani, Hamidreza Yadegari, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 3
Closed Access | Times Cited: 14
Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2
Michael D. Grant, Kirsten Bentley, Ceri A. Fielding, et al.
JCI Insight (2023) Vol. 8, Iss. 15
Open Access | Times Cited: 11
First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain
Leira Fernández‐Bastit, Jordi Rodon, Edwards Pradenas, et al.
Viruses (2021) Vol. 13, Iss. 12, pp. 2526-2526
Open Access | Times Cited: 25
Quantification of Severe Acute Respiratory Syndrome Coronavirus 2 Binding Antibody Levels To Assess Infection and Vaccine-Induced Immunity Using WHO Standards
Olivier Pernet, Steven Balog, Eric S. Kawaguchi, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 7
Spotlight on contributory role of host immunogenetic profiling in SARS-CoV-2 infection: Susceptibility, severity, mortality, and vaccine effectiveness
Somayeh Yazdanparast, Mehdi Bakhtiyaridovvombaygi, Fatemeh Mikanik, et al.
Life Sciences (2023) Vol. 328, pp. 121907-121907
Open Access | Times Cited: 7
Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein
Yuting Hong, Huilin Guo, Min Wei, et al.
Journal of Virological Methods (2022) Vol. 307, pp. 114564-114564
Open Access | Times Cited: 12
Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
Douglas F. Lake, Alexa J. Roeder, María J. González‐Moa, et al.
Communications Medicine (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 12
Identification of immunodominant epitopes on nucleocapsid and spike proteins of the SARS-CoV-2 in Iranian COVID-19 patients
Faezeh Maghsood, Mohammad-Reza Shokri, Mahmood Jeddi‐Tehrani, et al.
Pathogens and Disease (2022) Vol. 80, Iss. 1
Open Access | Times Cited: 11
Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and nucleocapsid protect hamsters against COVID-19
Mohadeseh Hasanpourghadi, Mikhail Novikov, Robert Ambrose, et al.
Microbes and Infection (2022) Vol. 25, Iss. 4, pp. 105082-105082
Open Access | Times Cited: 11
ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein
Rico Ballmann, Sven‐Kevin Hotop, Federico Bertoglio, et al.
Viruses (2022) Vol. 14, Iss. 6, pp. 1326-1326
Open Access | Times Cited: 10
Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2
Florencia Rammauro, Federico Carrión, Natalia Olivero‐Deibe, et al.
Vaccine (2022) Vol. 40, Iss. 35, pp. 5189-5196
Open Access | Times Cited: 10
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and humoral responses against different variants of concern in domestic pet animals and stray cats from North‐Eastern Spain
Leira Fernández‐Bastit, Sílvia Marfil, Edwards Pradenas, et al.
Transboundary and Emerging Diseases (2022) Vol. 69, Iss. 6, pp. 3518-3529
Open Access | Times Cited: 9
A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021
Kento T. Abe, Bhavisha Rathod, Karen Colwill, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 5
Production and characterization of a chimeric antigen, based on nucleocapsid of SARS-CoV-2 fused to the extracellular domain of human CD154 in HEK-293 cells as a vaccine candidate against COVID-19
Thailin Lao, Ileanet Avalos, Elsa Rodríguez, et al.
PLoS ONE (2023) Vol. 18, Iss. 9, pp. e0288006-e0288006
Open Access | Times Cited: 2
Blood‐derived product therapies for SARS‐CoV‐2 infection and long COVID
Junzheng Wu, Huichuan Yang, Ding Yu, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 2
The Papain-like Protease Domain of Severe Acute Respiratory Syndrome Coronavirus 2 Conjugated with Human Beta-Defensin 2 and Co1 Induces Mucosal and Systemic Immune Responses against the Virus
Byeol-Hee Cho, Ju Kim, Yong‐Suk Jang
Vaccines (2024) Vol. 12, Iss. 4, pp. 441-441
Open Access
Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice
Jacklyn R. Hurst, Maedeh Naghibosadat, Patrick Budowski, et al.
PLoS ONE (2024) Vol. 19, Iss. 12, pp. e0314061-e0314061
Open Access
ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-Cov-2 Spike Protein
Rico Ballmann, Sven‐Kevin Hotop, Federico Bertoglio, et al.
(2022)
Open Access | Times Cited: 3
Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study
Sean Liu, Mila Mirceta, Grace Lin, et al.
Antimicrobial Agents and Chemotherapy (2023)
Open Access | Times Cited: 1
Selection of plasma donors for the production of anti-SARS-CoV-2 immunoglobulin-based therapies: Strategies for quantitative antibody measurements
Bruno Deltreggia Benites, Carolina Costa-Lima, Fernanda Batista Rosa Pinto, et al.
Transfusion and Apheresis Science (2022) Vol. 61, Iss. 6, pp. 103513-103513
Open Access | Times Cited: 2
Transient Expression in HEK-293 Cells in Suspension Culture as a Rapid and Powerful Tool: SARS-CoV-2 N and Chimeric SARS-CoV-2N-CD154 Proteins as a Case Study
Thailin Lao, Omar Farnós, Alexi Bueno, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 3050-3050
Open Access
Page 1 - Next Page

Scroll to top